cerca CERCA
Mercoledì 24 Aprile 2024
Aggiornato: 04:34
10 ultim'ora BREAKING NEWS

Comunicato stampa

Sweegen's Statement Regarding PureCircle Lawsuit

19 settembre 2018 | 04.00
LETTURA: 1 minuti

RANCHO SANTA MARGARITA, California, Sept. 19, 2018 /PRNewswire/ -- PureCircle filed a complaint in the U.S. District Court for the Central District of California against Sweegen, Inc.  PureCircle claims that Sweegen's Bestevia® Reb-M is infringing PureCircle's patent -- U.S. Patent No. 9,243,273, A Method for Making Rebaudioside M (Reb-M).

Sweegen, together with its licensor, has 13 patents granted and over 130 patent applications pending worldwide regarding stevia sweeteners.  This impressive patent portfolio is focused on next generation stevia sweeteners and includes at least 7 novel methods for producing plant-based, non-GMO Reb-M. 

As the innovative provider of next generation stevia sweeteners, Sweegen sells zero-calorie, Non-GMO Project Verified, plant-based Reb-M and Reb-D for use in the food and beverage industry.  These next generation stevia sweeteners enable companies to offer sugar reduced products with the same sugar-like taste we have all grown to enjoy.  Such products include carbonated beverages, juices, yogurts, ice creams, nutritional foods, and confectionery goods such as cookies.  

Sweegen will defend and protect its strong IP position, with deepest respect to innovative Intellectual Property for the benefit of consumers globally.

About Sweegen

Sweegen (OTC: SWEE) is dedicated to the development, production and distribution of zero-calorie stevia sweeteners for the food, beverage and flavor industries. Sweegen's robust product pipeline, intellectual property portfolio, dedicated manufacturing capacity and R&D provide the company its foundation for innovation and delivery of high-quality sweeteners. For more information, please contact info@sweegen.com or visit Sweegen's website www.sweegen.com.

Logo - https://mma.prnewswire.com/media/469549/Sweegen_Final_OT_Logo.pdf  

Riproduzione riservata
© Copyright Adnkronos
Tag
Vedi anche


SEGUICI SUI SOCIAL



threads whatsapp linkedin twitter youtube facebook instagram
ora in
Prima pagina
articoli
in Evidenza